Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PGD | P52209 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16488404 | 1.00 | MAPK1 (0.37) | MAPK1NPSR1GAAPGD | |
| SCHEMBL14944925 | 1.00 | MAPK1 (0.37) | MAPK1NPSR1GAAPGD | |
| SCHEMBL16639432 | 1.00 | MAPK1 (0.37) | MAPK1NPSR1GAAPGD | |
| SCHEMBL7554691 | 0.85 | MAPK1 (0.42) | MAPK1NPSR1GAAPGD | |
| SCHEMBL682098 | 0.85 | MAPK1 (0.42) | MAPK1NPSR1GAAPGD | |
| SCHEMBL7551362 | 0.85 | MAPK1 (0.42) | MAPK1NPSR1GAAPGD | |
| SCHEMBL12638787 | 0.85 | MAPK1 (0.42) | MAPK1NPSR1GAAPGD | |
| SCHEMBL4243891 | 0.81 | SUCNR1 (0.38) | MAPK1NPSR1GAAPGD | |
| SCHEMBL15325118 | 0.81 | SUCNR1 (0.38) | MAPK1NPSR1GAAPGD | |
| SCHEMBL14527074 | 0.81 | SUCNR1 (0.38) | MAPK1NPSR1GAAPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921373-B2 | Compounds having TRPV1 antagonistic activity and uses thereof | SHIONOGI & CO., LTD. (JP) | 2014-12-30 | — | — | US | disclosed |
| US-20130123239-A1 | COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF | PURDUE PHARMA L.P. | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123239-A1 | COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF | TRPV1, TRPA1, TRPV2 | MAPK1 1718/4885NPSR1 104/4885GAA 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.